Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
International Journal of Molecular Sciences · 19.07.2023 · 24 (14) · 11624
DOI: 10.3390/ijms241411624 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2023. Verfasst von Salomé Coppens und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Measurement Laboratory, LGC Limited, Teddington TW11 0LY, UK. Hauptthemen laut MEDLINE: Intermediate Filaments, Axons. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation program Marie Curie ITN 'MIRIADE', European Union’s Horizon 2020 research and innovation program Marie Curie ITN ‘MIRIADE’.
Abstract (Originalsprache)
Neurofilament-light chain (Nf-L) is a non-specific early-stage biomarker widely studied in the context of neurodegenerative diseases (NDD) and traumatic brain injuries (TBI), which can be measured in biofluids after axonal damage. Originally measured by enzyme-linked immunosorbent assay (ELISA) in cerebrospinal fluid (CSF), Nf-L can now be quantified in blood with the emergence of ultrasensitive assays. However, to ensure successful clinical implementation, reliable clinical thresholds and reference measurement procedures (RMP) should be developed. This includes establishing and distributing certified reference materials (CRM). As a result of the complexity of Nf-L and the number of circulating forms, a clear definition of what is measured when immunoassays are used is also critical to achieving standardization to ensure the long-term success of those assays. The use of powerful tools such as mass spectrometry for developing RMP and defining the measurand is ongoing. Here, we summarize the current methods in use for quantification of Nf-L in biofluid showing potential for clinical implementation. The progress and challenges in developing RMP and defining the measurand for Nf-L standardization of diagnostic tests are addressed. Finally, we discuss the impact of pathophysiological factors on Nf-L levels and the establishment of a clinical cut-off.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Measurement Laboratory, LGC Limited, Teddington TW11 0LY, UK.
- Univ. Montpellier, IRMB-PPC, INM, CHU Montpellier, INSERM CNRS, 34295 Montpellier, France.
ORCID-Profile: Sylvain Lehmann, Christophe Hirtz
Förderung
- European Union's Horizon 2020 research and innovation program Marie Curie ITN 'MIRIADE'
- European Union’s Horizon 2020 research and innovation program Marie Curie ITN ‘MIRIADE’
Zitieren
APA
Coppens, S., Lehmann, S., Hopley, C., & Hirtz, C. (2023). Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges. International Journal of Molecular Sciences, 24(14), 11624. https://doi.org/10.3390/ijms241411624
Vancouver
Coppens S, Lehmann S, Hopley C, Hirtz C. Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges. International Journal of Molecular Sciences. 2023;24(14):11624. doi:10.3390/ijms241411624
BibTeX
@article{Coppens2023,
author = {Coppens, Salomé and Lehmann, Sylvain and Hopley, Christopher and Hirtz, Christophe},
title = {Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11624},
doi = {10.3390/ijms241411624}
}
EUVIMED